ICG-001 and C-82/PRI-724 specifically inhibit the interaction between CREBBP/β-catenin, but not EP300/β-catenin, thereby rendering drug-resistant CML-initiating cells to be sensitive to BCR-ABL tyrosine kinase inhibitors [131,132,133]. This evidence concerns the gene CREBBP and chronic myelogenous leukemia, BCR-ABL1 positive.